Worth Venture Partners, LLC Scynexis Inc Transaction History

Worth Venture Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.15 - $3.0 $218,595 - $570,249	-190,083 Reduced 39.98%	285,327 $855,000
Q4 2022 Feb 14, 2023	SELL	$1.46 - $2.49 $22,190 - $37,845	-15,199 Reduced 3.1%	475,410 $741,000
Q3 2022 Nov 14, 2022	SELL	$1.83 - $2.93 $127,931 - $204,830	-69,908 Reduced 12.47%	490,609 $1.18 Million
Q1 2022 May 16, 2022	BUY	$3.56 - $6.66 $241,325 - $451,468	67,788 Added 13.76%	560,517 $2.19 Million
Q4 2021 Feb 14, 2022	BUY	$4.94 - $7.69 $739,038 - $1.15 Million	149,603 Added 43.6%	492,729 $3.01 Million

Q2 2021 Aug 16, 2021	BUY	$6.5 - $9.97 $2.23 Million - $3.42 Million	343,126 New	343,126 $2.53 Million

15.4M

12.9K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $63.7M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Worth Venture Partners, LLC with notifications on news.